Werewolf Therapeutics
HOWL
49 hedge funds and large institutions have $84.3M invested in Werewolf Therapeutics in 2022 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 16 increasing their positions, 15 reducing their positions, and 8 closing their positions.
7% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 15
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.61% less ownership
Funds ownership: 69.4% → 68.79% (-0.61%)
4% less funds holding
Funds holding: 51 → 49 (-2)
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
63% less capital invested
Capital invested by funds: $228M → $84.3M (-$144M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$1.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.04M |
| 3 |
State Street
Boston,
Massachusetts
|
+$529K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$519K |
| 5 |
Millennium Management
New York
|
+$297K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$5.78M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$769K |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$450K |
| 4 |
CCM
CAAS Capital Management
New York
|
-$427K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$141K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$153 | -12,831 | Closed |
|
|
52
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$141K | -11,829 | Closed |
|
|
MIM
53
MetLife Investment Management
Whippany,
New Jersey
| – | -$136K | -11,421 | Closed |
|
|
MLICM
54
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$101K | -8,460 | Closed |
|
|
HNWAG
55
High Net Worth Advisory Group
Naples,
Florida
| – | -$6K | -500 | Closed |
|
|
CWS
56
Confluence Wealth Services
Mcmurray,
Pennsylvania
| – | -$1K | -100 | Closed |
|
HOWL Hedge Fund Activity: Q1 2022 in Review
49 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Werewolf Therapeutics (HOWL) for Q1 2022, worth a combined $84.3M — down 63% from $228M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of HOWL and 6 opened new positions — a net loss of 2 holders — while 15 trimmed existing stakes and 16 added.
The largest buyer was PFM Health Sciences, adding an estimated $1.3M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $5.78M sold.
- 49 institutional investors held Werewolf Therapeutics (HOWL) as of Q1 2022, down from 51 in Q4 2021.
- Funds reported $84.3M of Werewolf Therapeutics stock for Q1 2022, down 63% quarter-over-quarter.
- 6 funds opened new Werewolf Therapeutics positions in Q1 2022 and 8 closed out, a net change of -2 holders.
- The largest Werewolf Therapeutics buyer in Q1 2022 was PFM Health Sciences, an estimated $1.3M added.
- The largest Werewolf Therapeutics seller in Q1 2022 was Avidity Partners Management, an estimated $5.78M sold.
Based on aggregated 13F filings for Q1 2022.